Holen Sie sich die Stockscreener-App
1.51
0.11%
-0.0017
Handel nachbörslich:
1.56
0.05
+3.31%
Schlusskurs vom Vortag:
$1.5117
Offen:
$1.5485
24-Stunden-Volumen:
23,604
Relative Volume:
0.15
Marktkapitalisierung:
$39.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.27M
KGV:
-9.2073
EPS:
-0.164
Netto-Cashflow:
$-7.70M
1W Leistung:
+23.77%
1M Leistung:
+8.63%
6M Leistung:
+19.84%
1J Leistung:
+4.38%
1-Tages-Spanne:
$1.50
$1.5786
1-Wochen-Bereich:
$1.14
$1.7099
52-Wochen-Spanne:
$0.8075
$1.74
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OKYO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.51 | 39.71M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN
Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news
OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com India
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
OKYO Pharma confirms stability of drug candidate - Investing.com
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World
Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - marketscreener.com
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment | NASDAQ:OKYO - Proactive Investors
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive financial news
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks
Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria
OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa
OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):